Atlas Trials

A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTients

Clinical trial NCT03561740 · RECRUITING

Trial details

NCT number
NCT03561740
Sponsor
Sun Yat-sen University
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Breast Cancer
Start date
2018-07-25
Primary completion
2023-06-15
Enrollment
794

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.